Cryo-Fluorescence Tomography (CFT) is powerful technique for cancer biology applications. Xerra™ can play a key role for studying tumor models including microenvironments, tumor heterogeneity, metastatic spread, and expression of specific biomarkers. For metastatic tumor progression, CFT can detect metastatic disease and provides high resolution 3D molecular data of tumor burden and spread not typically visualized incomparable image modalities. In addition, CFT also provides whole body white light imaging for anatomical landmarking for tumor localization. CFT can be used to evaluate tumor metabolism and cell biology in response to genetic manipulations, pharmacologic agents, and cancer chemotherapy drugs.
Cryo-fluorescence tomography (CFT) is a molecular tissue imaging modality combining tissue cryoslicing and off-the-block fluorescence imaging. CFT does not require radiolabels, radiofrequency, or the use of ionizing radiation to image a sample. CFT relies on streamlined fluorescence imaging of a tissue or whole animal and produces high resolution data without the need for complex infrastructure or workflow. CFT’s high specificity, high resolution, and low light scatter can integrate with current in vivo imaging techniques and complement a study design with endpoint data.
CFT – your partner in glioblastoma research
CFT is a great tool to study glioblastomas, a common type of brain tumor in adults. In this experiment, malignant glioma was recreated in an immunocompromised mouse by injecting GL26-luc2 cells in the brain. 2 weeks later, an MRI of the brain was done. Angiosense 680Ex and indocyanine green (ICG) dyes were used to visualize blood vessels. CFT was used to capture images. Image stacks were aligned, corrected and reconstructed. 3D distribution and quantification of Angiosense and ICG, as well as 3D white light information. In this study, CFT provided valuable information in preclinical oncology models.